ReviewNature reviews. Urology2025
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.
Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07272317 (PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy), which is not on this map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial
Who cites it
100 citing papers in PubMed.
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- First-in-human evaluation of [Annals of medicine · 2026Article
- Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.British journal of cancer · 2026Article
- Bridging the Resolution Gap in Recurrent Prostate Cancer Imaging: Quantum Dots as PSMA-Targeted Optical Probes.ACS omega · 2026Review
- Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study.European journal of nuclear medicine and molecular imaging · 2026Article
- Multiscale Transcriptomic and Molecular Modeling Analyses Suggest DCPMU-Associated Epithelial Remodeling and Tumor Microenvironment Perturbation in Prostate Cancer.Current issues in molecular biology · 2026Article
- Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- A Preliminary Evaluation ofPharmaceutics · 2026Article
- Imaging and Clinical Correlates of [Biomedicines · 2026Article
- Chemical Scaffolds Driving Modern Anticancer Drug Discovery and Radiotheranostics: Structural Determinants, Translational Opportunities and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Challenges of Bone Scintigraphy in Assessment of Osseous Metastases in Prostate Cancer: Why it is Time to Reconsider Role ofMolecular imaging and biology · 2026Review
- Identifying genetics biomarkers in correlation with pathological and PSMA PET/CT characteristics in prostate cancer.EJNMMI research · 2026Article
- When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Article
- A prostate-specific membrane antigen targeted small molecule-drug conjugate for efficient prostate cancer therapy at a low dosage.International journal of pharmaceutics: X · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker and therapeutic target in prostate cancer. The PSMA-targeted theranostic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.